Trial Profile
A Phase II Trial of Ofatumumab (CALGB IND) in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 16 Aug 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700009482, 700028982, 70057042) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.